Hongming Pan

23.5k total citations · 6 hit papers
222 papers, 9.2k citations indexed

About

Hongming Pan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hongming Pan has authored 222 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 92 papers in Pulmonary and Respiratory Medicine and 68 papers in Molecular Biology. Recurrent topics in Hongming Pan's work include Lung Cancer Treatments and Mutations (49 papers), Colorectal Cancer Treatments and Studies (48 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Hongming Pan is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Colorectal Cancer Treatments and Studies (48 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Hongming Pan collaborates with scholars based in China, United States and Taiwan. Hongming Pan's co-authors include Weidong Han, Xinbing Sui, Ju-Jun Xie, Na Kong, Chao He, Xian Wang, Jichun Zhou, Qin Zhang, Li Ye and Liangkun You and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hongming Pan

220 papers receiving 9.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

2013 1.0k citations Xinbing Sui, Weidong Han et al. profile →
p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents

2013 815 citations Xinbing Sui, Weidong Han et al. profile →
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 553 citations Shukui Qin, Rui‐Hua Xu et al. profile →
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Shukui Qin, Hongming Pan et al. Journal of Clinical Oncology profile →
The role of STAT3 in autophagy

2015 418 citations Liangkun You, Zhanggui Wang et al. profile →
CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer

2022 146 citations Sheng Jin, Hongming Pan et al. profile →

Peers

Countries citing papers authored by Hongming Pan

Since Specialization

Citations

This map shows the geographic impact of Hongming Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongming Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongming Pan more than expected).

Fields of papers citing papers by Hongming Pan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongming Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongming Pan. The network helps show where Hongming Pan may publish in the future.

Co-authorship network of co-authors of Hongming Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Hongming Pan. A scholar is included among the top collaborators of Hongming Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongming Pan. Hongming Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploration and machine learning model development for T2 NSCLC with bronchus infiltration and obstructive pneumonia/atelectasis 2024 ·Scientific Reports ·(unknown), Pan Yang, (unknown), (unknown), Liangkun You, Hongming Pan	1
2	Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence 2024 ·JCO Precision Oncology ·(unknown), Hongming Pan, Jean Frédéric Blanc, Véronique Grando, Ho Yeong Lim, (unknown), Aurora O’Brate, Christopher Stroh, Manja Friese‐Hamim, Joachim Albers, Andreas Johne, Sandrine Faivre	6
3	First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors 2024 ·BMC Cancer ·Ye Guo, Zishu Wang, Huan Zhou, Hongming Pan, Weidong Han, Yanhong Deng, Qun Li, Junli Xue, Xiaoxiao Ge, Shuang Wang, Jing Wang, Yue Zhang, (unknown), (unknown), Yu Wang, Haige Shen, (unknown), Jin Li	7
4	172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial 2023 ·Annals of Oncology ·Lin Shen, Pei Chen, Jun Lü, Yueping Wan, Yang Zheng, Fayin Ye, Jingcheng Yang, Y. Liu, Hongming Pan, Hui Chen, Meili Sun, Qiang Fan, Yuan Yang, Ken Chen, Ziyong Sun, He Tian, (unknown), Zhi Peng	6
5	SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Jun Zhao, Xinmin Yu, Dingzhi Huang, Zhiyong Ma, Bo Gao, Jiuwei Cui, Qian Chu, Qing Zhou, Meili Sun, Daphne Day, Jingxun Wu, Hongming Pan, Lifeng Wang, Mark Voskoboynik, Zhehai Wang, Yunpeng Liu, Hui Li, Juan Zhang, (unknown), Yi‐Long Wu	15
6	Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study 2023 ·BMC Cancer ·Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, (unknown), Qing Xu, (unknown), Xuan Wang, (unknown), Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, (unknown), Qian Tan, Di Wu, Jun Guo	6
7	GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study. 2023 ·Journal of Clinical Oncology ·Ye Guo, Zishu Wang, Huan Zhou, Hongming Pan, Weidong Han, Yanhong Deng, Yanqiao Zhang, Yue Zhang, Shuang Wang, Jing Wang, (unknown), Haige Shen, Yu Wang, Jin Li	2
8	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma 2022 ·Clinical Cancer Research ·Andrew X. Zhu, Farshid Dayyani, Chia‐Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K. Mhatre, Vincent E. Gaillard, Sairy Hernandez, Robin Kate Kelley, Bruno Sangro	75
9	The roles of transmembrane family proteins in the regulation of store-operated Ca2+ entry 2022 ·Cellular and Molecular Life Sciences ·(unknown), Hongming Pan, X. H. Liang, Ju-Jun Xie, Weidong Han	12
10	LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression 2021 ·Journal of International Medical Research ·Lili Liu, Hua Jiang, Hongming Pan, Xiuming Zhu	20
11	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression 2021 ·British Journal of Cancer ·Baek‐Yeol Ryoo, Ann‐Lii Cheng, Zhenggang Ren, Tae‐You Kim, Hongming Pan, Kun-Ming Rau, Hye Jin Choi, Joong‐Won Park, Jee Hyun Kim, (unknown), Ho Yeong Lim, Dongli Zhou, Josef Straub, (unknown), Karin Berghoff, Shukui Qin	36
12	Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy 2021 ·Advanced Materials ·Honglin Tang, Xiaojie Xu, Yuxuan Chen, Huhu Xin, Tao Wan, Bowen Li, Hongming Pan, Da Li, Ping Yuan	185
13	Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody 2021 ·Frontiers in Molecular Biosciences ·Sheng Jin, (unknown), Xiao Liu, (unknown), (unknown), Pengfei Xu, Jiawei Shou, Hong Pan, Hongsen Li, Xiaoyun Zhou, Weidong Han, Tao Sun, Hongming Pan, Yong Fang	13
14	TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10 2018 ·PLoS Biology ·Peng Tan, Youqiong Ye, Lian He, Ju-Jun Xie, Jing Ji, Guolin Ma, Hongming Pan, Leng Han, Weidong Han, Yubin Zhou	75
15	Predictive biomarkers for tumor immune checkpoint blockade 2018 ·Cancer Management and Research ·Mengting Tong, Jing Wang, Wenting He, Yanling Wang, Hongming Pan, (unknown), Hongliang Zhang	15
16	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study 2017 ·Journal of Hematology & Oncology ·Rui‐Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Hua Ye, Weiguo Su	63
17	Relationship of metformin with the risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis 2017 ·Biomedical Research-tokyo ·(unknown), Yong Fang, Xiaoyun Zhou, (unknown), Lili Liu, Wei Wang, (unknown), (unknown), (unknown), Yong Dong, Hongming Pan	3
18	The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells 2014 ·Biochemical and Biophysical Research Communications ·Haizhou Lou, (unknown), Hongming Pan, Pan Qin, Peng Sun, Liu Lili, Bin Chen	25
19	Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib 2014 ·Scientific Reports ·Hongming Pan, Zhanggui Wang, Liming Jiang, Xinbing Sui, Liangkun You, Jiawei Shou, Jing Zhao, Ju-Jun Xie, Weiting Ge, Xiujun Cai, Wendong Huang, Weidong Han	58
20	Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo 2013 ·Cancer Cell International ·Pan Qin, Hongming Pan, Haizhou Lou, Yinghua Xu, Lü Tian	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact